Skip to main content
Top
Published in: Infectious Agents and Cancer 1/2013

Open Access 01-12-2013 | Editorial

Infections and cancer: debate about using vaccines as a cancer control tool

Authors: Sam M Mbulaiteye, Franco M Buonaguro

Published in: Infectious Agents and Cancer | Issue 1/2013

Login to get access

Abstract

In 2012, Infectious Agents and Cancer commissioned a thematic series collection of articles on Prevention of HPV related cancer. The articles have attracted wide interest and stimulated debate, including about the utility of vaccines in cancer control. The application of vaccines to cancer control fulfills a promise envisioned at the turn of the 20th century when remarkable experiments showed that some cancers were caused by infections. This suggested the possibility of applying infection-control strategies to cancer control. Vaccines represent the most practical cost-effective technology to prevent wide human suffering and death from many acute infectious diseases, such as small pox or polio. Hitherto applied to control of acute fatal infections, vaccines, if developed, might provide a potent way to control cancer. The articles in the HPV thematic series show success in developing and applying a vaccine against human papilloma virus (HPV). A vaccine is also available against hepatitis B virus (HBV), which causes liver cancer. These vaccines augment the tools available to control the associated cancers. Scientific endeavor continues for six other cancer-associated infections, mostly viruses. Not surprisingly, debate about the safety of vaccines targeting cancer has been triggered in the scientific community. Questions about safety have been raised for those populations where other means to control these cancers may be available. Although it is difficult to quantify risk from vaccines in individuals where other cancer control services exist, it is likely to be low. Vaccines are much safer today than before. Technological advancement in vaccine development and manufacture and improved regulatory review and efficient distribution have minimized substantially the risk for harm from vaccines. Formal and informal debate about the pros and cons of applying vaccines as a cancer control tools is ongoing in scientific journals and on the web. Infectious Agents and Cancer encourages evidence-based discussion to clarify understanding of the role of vaccines in cancer control. In a similar vein, the journal will not consider anecdotal reports and rhetorical arguments because they are unlikely to inform policy, regulation, or the public.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aylward B, Tangermann R: The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011, 29 (S4): D80-85. 10.1016/j.vaccine.2011.10.005.PubMedCrossRef Aylward B, Tangermann R: The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011, 29 (S4): D80-85. 10.1016/j.vaccine.2011.10.005.PubMedCrossRef
2.
go back to reference Needham J: Science and Civilization in China. Volume 6, Biology and Biological Technology, Part 6, Medicine. 1999, Cambridge: Cambridge University Press, 134- Needham J: Science and Civilization in China. Volume 6, Biology and Biological Technology, Part 6, Medicine. 1999, Cambridge: Cambridge University Press, 134-
3.
go back to reference Hopkins DR: The greatest killer: smallpox in history, with a new introduction. 2002, : University Of Chicago Press, 978-0-226-35168-1 Hopkins DR: The greatest killer: smallpox in history, with a new introduction. 2002, : University Of Chicago Press, 978-0-226-35168-1
4.
go back to reference Jenner E: An inquiry into the causes and effects of the variolæ vaccinæ, a disease discovered in some of the Western Counties of England, particularly Gloucestershire, and known by the name of the cow pox. 1798, London: Printed by Sampson Low, Reprinted Project Guttemberg 2009 Jenner E: An inquiry into the causes and effects of the variolæ vaccinæ, a disease discovered in some of the Western Counties of England, particularly Gloucestershire, and known by the name of the cow pox. 1798, London: Printed by Sampson Low, Reprinted Project Guttemberg 2009
8.
go back to reference Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch XF, de Sanjosé S: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer. 2012, 7: 38-10.1186/1750-9378-7-38.PubMedPubMedCentralCrossRef Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch XF, de Sanjosé S: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer. 2012, 7: 38-10.1186/1750-9378-7-38.PubMedPubMedCentralCrossRef
9.
go back to reference Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA: HPV vaccines and cancer prevention, science versus activism. Infectious Agents and Cancer. 2013, 8: 6-10.1186/1750-9378-8-6.PubMedPubMedCentralCrossRef Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA: HPV vaccines and cancer prevention, science versus activism. Infectious Agents and Cancer. 2013, 8: 6-10.1186/1750-9378-8-6.PubMedPubMedCentralCrossRef
10.
go back to reference Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V: WHO - Intl Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009, 10 (4): 321-2. 10.1016/S1470-2045(09)70096-8.PubMedCrossRef Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V: WHO - Intl Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009, 10 (4): 321-2. 10.1016/S1470-2045(09)70096-8.PubMedCrossRef
11.
go back to reference Offit PA: Thimerosal and vaccines–a cautionary tale. N Engl J Med. 2007, 357 (13): 1278-9. 10.1056/NEJMp078187.PubMedCrossRef Offit PA: Thimerosal and vaccines–a cautionary tale. N Engl J Med. 2007, 357 (13): 1278-9. 10.1056/NEJMp078187.PubMedCrossRef
12.
go back to reference Offit PA: Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. 2007, New York, NY: Harper Collins Publishers Inc Offit PA: Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases. 2007, New York, NY: Harper Collins Publishers Inc
13.
go back to reference Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013, 346: 2032-10.1136/bmj.f2032.CrossRef Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013, 346: 2032-10.1136/bmj.f2032.CrossRef
14.
go back to reference Buonaguro FM, Tornesello ML, Buonaguro L: Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines. 2010, 9 (8): 805-807. 10.1586/erv.10.95.PubMedCrossRef Buonaguro FM, Tornesello ML, Buonaguro L: Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines. 2010, 9 (8): 805-807. 10.1586/erv.10.95.PubMedCrossRef
15.
go back to reference Buonaguro FM, Butler-Ransohoff JE: PharmaPlant: the new frontier in vaccines. Expert Rev Vaccines. 2010, 9 (8): 7-805. 10.1586/erv.10.95.CrossRef Buonaguro FM, Butler-Ransohoff JE: PharmaPlant: the new frontier in vaccines. Expert Rev Vaccines. 2010, 9 (8): 7-805. 10.1586/erv.10.95.CrossRef
16.
go back to reference Buonaguro F, Buonaguro L: The application of virus-like particles to human diseases. Expert Rev Vaccines. 2013, 12 (2): 99-10.1586/erv.12.154.PubMedCrossRef Buonaguro F, Buonaguro L: The application of virus-like particles to human diseases. Expert Rev Vaccines. 2013, 12 (2): 99-10.1586/erv.12.154.PubMedCrossRef
Metadata
Title
Infections and cancer: debate about using vaccines as a cancer control tool
Authors
Sam M Mbulaiteye
Franco M Buonaguro
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2013
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-8-16

Other articles of this Issue 1/2013

Infectious Agents and Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine